Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. reported fiscal third-quarter 2026 revenue of $2.2 million, up 105% from $1.1 million a year earlier, driven by growing adoption of its LungFit PH nitric oxide system in the U.S. and abroad. Gross profit improved to $0.3 million from a gross loss of $0.2 million.
Operating costs declined, with research and development down to $2.4 million and selling, general and administrative expenses reduced to $4.5 million. Net loss attributable to common stockholders narrowed to $7.3 million, or $0.85 per share, compared with a $13.0 million loss, or $2.96 per share, in the prior-year quarter.
The company ended the quarter with $17.8 million in cash, cash equivalents, restricted cash and marketable securities, plus $4.5 million of net proceeds from a subsequent private placement, and believes this supports a cash runway into calendar 2027. It maintained fiscal 2026 revenue guidance of $8–10 million and reported total long-term debt of $22.0 million.
Beyond Air highlighted commercial milestones, including its first LungFit PH sale to a VA Medical Center and international distribution now covering 40 countries. It also noted a binding agreement under which XTL Biopharmaceuticals will acquire 85% of NeuroNOS, with Beyond Air eligible for $1.0 million in cash, up to $31.5 million in milestones, and 19.9% equity in XTL.
Beyond Air, Inc. reported higher revenue but continuing losses for the quarter ended December 31, 2025. Revenue rose to $2.2 million from $1.1 million a year earlier, driven mainly by LungFit PH lease revenue, yet gross profit was only $0.3 million as costs remained high.
The company posted a quarterly net loss attributable to Beyond Air of $7.3 million, versus $13.0 million a year prior, and a nine‑month net loss of $23.0 million. Operating cash use for the nine months was $13.2 million. As of December 31, 2025, cash, cash equivalents, marketable securities and restricted cash totaled $17.8 million, with an accumulated deficit of $309.3 million and long‑term debt of $22.0 million.
Management states that these factors raise “substantial doubt” about the ability to meet obligations without new capital and concluded additional funding will be required within one year of issuance of these statements. To bolster liquidity, the company issued an $11.5 million secured loan and a $12.0 million secured promissory note in late 2024 and 2025, and completed a $5.0 million private placement on January 16, 2026. Beyond Air also gained a European CE mark for LungFit PH in November 2024 and effected a 1‑for‑20 reverse stock split in July 2025. Shares outstanding were 10,529,344 as of February 10, 2026.
Beyond Air, Inc. has filed a prospectus covering the resale of 524,990 shares of common stock, 3,405,828 shares issuable upon exercise of pre-funded warrants, and 3,930,818 shares issuable upon exercise of common warrants by existing investors. The company will not receive proceeds from these resales, but could receive cash if the warrants are exercised. Shares outstanding were 10,529,344 as of January 22, 2026, rising to 17,865,990 assuming full warrant exercise. Recent developments include a $12.05 million secured note at 15% interest, a $20 million equity purchase agreement with Streeterville Capital, expanded credit from insider lenders, and a binding letter of intent to sell its 85% stake in NeuroNOS Ltd. for cash, XTL Biopharmaceuticals equity, and up to $31.5 million in milestones. LungFit PH has also received European CE mark approval, broadening its approved indications beyond the United States.
Beyond Air, Inc. reported voting results from its 2026 Annual Meeting of Stockholders. Out of 8,009,488 shares outstanding as of December 3, 2025, a quorum of 4,221,408 shares, or 52.70%, was represented in person or by proxy.
Stockholders elected six directors to serve until the next annual meeting or until their successors are qualified. They also ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending March 31, 2026.
In addition, stockholders approved the Eighth Amended and Restated 2013 Equity Incentive Plan, increasing shares reserved for issuance by 850,000, and approved the option to adjourn the meeting, although adjournment was not needed because all key proposals passed.
Beyond Air, Inc. has filed an S-3 shelf registration to allow existing investors to resell common stock and shares issuable from previously issued warrants. The filing covers 524,990 outstanding common shares, plus additional shares issuable from pre-funded warrants and common warrants.
The pre-funded warrants are exercisable at $0.0001 per share, and the common warrants are exercisable at $1.147 per share through January 16, 2031. Beyond Air will not receive proceeds from stockholder resales, but would receive cash if holders exercise these warrants. Shares outstanding were 10,529,344 as of January 22, 2026, and would be 17,865,990 if all warrant shares in this filing are issued.
Beyond Air, Inc. entered into a private placement with an institutional investor, agreeing to sell 524,990 common shares at $1.272 per share, pre-funded warrants to purchase up to 3,405,828 shares at $1.2719 per warrant, and common warrants to purchase up to 3,930,818 shares, for aggregate gross proceeds of $5,000,000. The pre-funded warrants have a nominal exercise price of $0.0001 per share and the common warrants have an exercise price of $1.147 per share and expire on January 16, 2031. The company agreed to register the resale of the shares and warrant shares by filing a registration statement by February 4, 2026, with effectiveness targeted within 60 to 90 days after January 14, 2026, and may owe liquidated damages if these deadlines are missed. Beyond Air will pay Rodman & Renshaw LLC a cash fee of 7% of gross proceeds and reimburse up to $50,000 of expenses and is subject to specified restrictions on additional equity issuances and variable rate transactions for defined periods.
Beyond Air, Inc. reported that XTL Biopharmaceuticals Ltd. has signed a binding letter of intent to acquire Beyond Air’s 85% ownership interest in NeuroNOS Ltd., a biotechnology company developing disease‑modifying therapeutics for Autism Spectrum Disorder and neuro‑oncology. Under the proposed terms, Beyond Air would receive 19.9% of XTL’s issued share capital, $1 million in cash, and milestone-based contingent payments of up to $31.5 million.
The companies are working to finalize definitive agreements for the transaction, which are expected to be filed in a future current report or in Beyond Air’s Annual Report on Form 10‑K. The disclosure emphasizes that these statements are forward‑looking and may differ from actual results.
Beyond Air, Inc. granted its Chief Financial Officer, Daniel J. Moorhead, a new stock option award. On January 5, 2026, he received an inducement grant of options to buy 70,000 shares of common stock at an exercise price of $0.79 per share, matching the closing price on January 2, 2026. The options expire on January 4, 2036.
According to the vesting terms, 25% of the options vest on the one-year anniversary of January 5, 2026, and the remaining 75% vest in three equal annual installments after that, as long as he remains employed. Any portion that is unexercisable when his employment ends will not become exercisable later. After this grant, he beneficially owns 70,000 stock options directly.
Beyond Air, Inc. is registering up to 1,600,000 shares of common stock for resale by Streeterville Capital, LLC. These shares may be issued to Streeterville under a $20 million Equity Purchase Agreement and, in some cases, as share issuances used to offset amounts outstanding under a $12,050,000 secured promissory note. Beyond Air will not receive proceeds from Streeterville’s resale of the registered shares, but may receive cash when it sells stock to Streeterville under the purchase agreement.
As of December 8, 2025, Beyond Air had 8,009,488 shares outstanding and a 4.99% beneficial ownership cap limits Streeterville’s holdings after each put. The company plans to use any cash raised from sales to Streeterville for general corporate purposes, including working capital, commercial operations, repayment of the note, and pre-clinical and clinical activities.
Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on its LungFit® nitric oxide platform, including the LungFit® PH system, which has FDA approval and a European CE mark for specific respiratory and cardiac indications.